Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment

BACKGROUND: Tenofovir (TDF) is considered as the first line therapy for chronic hepatitis B. This study presents the results of TDF monotherapy in patients who failed previous nucleoside analogue treatment. METHODS: The study included 29 patients treated with TDF 245 mg once daily for 18 months afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozielewicz, Dorota, Halota, Waldemar, Wietlicka-Piszcz, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778152/
https://www.ncbi.nlm.nih.gov/pubmed/26612013
http://dx.doi.org/10.1007/s12072-015-9681-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778152/
https://www.ncbi.nlm.nih.gov/pubmed/26612013
http://dx.doi.org/10.1007/s12072-015-9681-6

Ejemplares similares